{"classes":[{"categories":[{"measurements":[{"comment":"The geometric coefficient of variation was not estimable as a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"5.54"},{"comment":"The geometric coefficient of variation was not estimable as a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"16.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"117","value":"96.9"},{"groupId":"OG003","spread":"16.2","value":"314"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG004","spread":"105","value":"559"},{"groupId":"OG005","spread":"36.1","value":"766"},{"groupId":"OG006","spread":"34.8","value":"325"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"comment":"The geometric coefficient of variation was not estimable as a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"28.2"},{"groupId":"OG002","spread":"69.1","value":"37.9"},{"groupId":"OG003","spread":"145","value":"312"},{"groupId":"OG004","spread":"337","value":"584"},{"groupId":"OG005","spread":"31.4","value":"1490"},{"groupId":"OG006","spread":"333","value":"136"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"}],"units":"Participants"}],"description":"AUClast of TAK-186 was reported. As prespecified in the analysis plan, all participants in this combined cohort received the same target dose level of TAK-186. Therefore, data from these participants were pooled and analyzed as a single cohort.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.","id":"OG000","title":"Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone"},{"description":"Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.","id":"OG001","title":"Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.","id":"OG002","title":"Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.","id":"OG003","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone"},{"description":"Participants in Dose Escalation Phase and Cohort Expansion Phase received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG004","title":"Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.","id":"OG005","title":"Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone premedication was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.","id":"OG006","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population. Here, \"Overall Number of Participants Analyzed\" signifies the participants who were evaluable for this outcome measure \\& \"number analyzed\" signifies participants at the specific categories. TAK-186 was administered QW and had a lead-in dosing (LiD) regimen including 1-step and 2-step lead-in. Analysis at the lead-in dose time points was not possible due to insufficient data points.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Post-dose on Days 1, 8 and 15; Cycle 2: Post-dose Day 1 (Each cycle is 56 days)","title":"AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for TAK-186","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}